Liankang Biotechnology Group (00690.HK) issued an announcement that the listing application submitted by the group's independently developed Bogutai (Terripatide Injection) was accepted by the China National Drug Administration (NMPA) on June 28, 2022, with the acceptance number "CXSS2200062 Country". If the company developed Bogutai? obtained a marketing license, it will provide patients with better medication options, which is a major milestone for the company in the field of orthopedic diseases.
As of the close of June 28, 2022, Liankang Biotechnology Group (00690.HK) closed at 0.07 yuan, down 1.35%, with a turnover rate of 0.0%, a trading volume of 100,000 shares and a trading volume of 7,100,000 yuan. Investment banks have little attention to the stock, and no investment bank has given it a rating within 90 days.
Liankang Biotechnology Group has a market value of 471 million yuan, ranking 49th in the biotechnology II industry. The main indicators are shown in the table below:

and above are compiled by Securities Star based on public information. If you have any questions, please contact us.